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Abstract
Background—Persistent low-level viremia (LLV) during the treatment of antiretroviral therapy 
(ART) is associated with emergent drug resistance mutation (DRM); however insight into its 
driver is limited. The objectives were to study HIV-1 pol sequence evolution in subjects with 
persistent LLV and evaluate factors associated with sequence changes.
Methods—HIV-1 pol sequences from 54 treatment-naive subjects undergoing first-line 
lopinavir-ritonavir- or efavirenz-containing ART were obtained at pre-ART and end of LLV. 
HIV-1 sequence evolution was evaluated using phylogenetic analysis and hamming distance 
calculation. DRMs were interpreted based on the International AIDS Society-USA 2011 update.
Results—Subjects with new DRM during LLV had greater HIV-1 evolution across pol from the 
pre-ART to end of LLV compared to subjects without DRM. Evolution over non-DRM sites was 
similar between groups. Higher degree of genetic evolution was positively associated with higher 
HIV-1 RNA levels during LLV, both at DRM and non-DRM sites.
Conclusion—The magnitude of LLV was the primary driver of evolution rate at DRM as well as 
non-DRM sites. Higher viral load was associated with DRM emergence in these subjects. These 
findings provide insights that may be applicable to the management of patients with persistent 
LLV during ART.
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Introduction
Persistent low-level viremia (LLV), defined as multiple confirmed detectable HIV-1 RNA 
levels that are < 1,000 copies/mL, are commonly seen in HIV-1 infected subjects 
undergoing antiretroviral treatment (ART) and their significance to clinical outcome is 
increasingly recognized [1–5]. Previous studies evaluating drug resistance mutation (DRM) 
as a binary variable (present or absent) have shown emergence of DRM during persistent 
LLV, but insight into its drivers is limited [6–10]. We used a phylogenetic model and a 
modified Hamming distance calculation to quantify sequence evolution in the HIV-1 pol 
gene at both DRM and non-DRM sites of HIV-1 from pre- ART to the end of persistent 
LLV. We also evaluated factors associated with observed sequence changes.
Methods
Subjects were identified retrospectively from two AIDS Clinical Trials Group (ACTG) 
studies (A5142 and A5095) of first-line lopinavir-ritonavir- or efavirenz-containing ART 
[6]. Persistent LLV was defined as at least two VLs > 50 and < 1000 copies/mL over a 24-
week period after at least 24 weeks of ART. The end of LLV was the first VL ≤ 50 or ≥ 
1000 copies/mL after the LLV period [6]. VL was measured using ultrasensitive Roche 
Amplicor HIV-1 Monitor assay version 1.0 and/or 1.5. Samples preparation and population 
sequencing methods were described previously [6].
Within the HIV-1 pol sequence, we interrogated 987 nucleotide positions (329 amino acids: 
protease codon 1–99 and reverse transcriptase codon 1–230). There were 46 DRM sites 
including 31 reverse transcriptase and 15 major protease mutation sites based on the 
International AIDS Society-USA 2011 update [11]. For each subject, paired HIV-1 
sequences (pre-ART and the final sequence of LLV) were used to characterize HIV-1 
sequence evolution using two different approaches.
1. Phylogenetic analysis calculated nucleotide substitution rates for each subject based 
on Tamura-Nei (TN93) model. Pairwise TN93 distances were computed and 
normalized by follow-up time using PolEvolution scripts in HyPhy package [12]. 
TN93 model was selected because it corrects for biases in unequal base 
composition and differences in transition/transversion rates seen in nucleotide 
sequence evolution of HIV-1 [12].
2. Modified Hamming distance [13] measured the percentage mismatch in nucleotides 
and amino acids between HIV-1 sequences obtained pre-ART and the end of LLV. 
To accommodate mixture amino acids, i.e. for partially matched and complete 
mismatch nucleotides or amino acids, the distance was assigned a value of 0.5 and 
1, respectively. This distance is normalized by the sequence length but does not 
take into account the time span between the two isolates.
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In the HyPhy package, global nucleotide substitution rates were compared between groups 
using a likelihood-ratio test (LRT). Differences in Hamming distances between groups were 
compared using Wilcoxon rank-sum tests. Metrics of HIV-1 viremia [6] and the magnitude 
of sequence evolution (nucleotide substitution rates and Hamming distances) were 
correlated using Spearman’s rank coefficient. In addition to the methods described above, 
we also calculated synonymous (dS) and non-synonymous (dN) substitution rates based on 
the method of Nei and Gojobori [14] using SNAP (Synonymous and Non-synonymous 
Analysis Program) v1.1.1 [15–17].
Results
Fifty-four subjects had pol sequence data available before treatment and at the end of LLV 
(median pre-ART VL = 5.1 log10 copies/mL, [25th, 75th quantiles]: 4.7, 5.7). The median 
duration of follow-up between pre-ART and the end of LLV was 78 weeks (25th, 75th: 64, 
104) and median duration of LLV was 32 weeks (25th, 75th: 24, 40). New resistance 
mutations were detected during LLV in 20/54 (37%) subjects. The 20 subjects with new 
DRM during LLV had greater HIV-1 sequence evolution (nucleotide substitution rate [95% 
CI]:5.1×10−3 substitutions/site/year [4×10−3 – 6×10−3]) from pre-ART to final LLV 
sequence compared to subjects without new DRM (3.9 ×10−3 [3×10−3 – 4×10−3]) across the 
pol sequence (P=0.011). Greater sequence evolution in those with new DRM was also 
observed when analyzing by initial regimen (efavirenz + nucleoside analogs (NRTIs): 
4.5×10−3 [4×10−3–6×10−3] vs. 1.4×10–3 [1×10−3–2×10−3], p<0.001; lopinavir/ritonavir + 
NRTIs: 7.2 ×10−3 [5×10−3–9×10−3] vs. 4.1 ×10−3 [3×10−3–5×10−3], p=0.002). Over non-
DRM sites, global nucleotide substitution rates were similar between new DRM vs. non-
DRM groups (3.9 ×10−3 [3×10−3–5×10−3] vs. 3.7×10−3 [3×10−3–4×10−3], P=0.68).
Restricting to 20 subjects who developed DRM during LLV, 10 subjects who had VL > 200 
copies/mL at the time DRM was detected had much higher nucleotide substitution rate 
across pol sequence from pre-ART to the end of LLV compared to those with VL < 200 
copies/mL at the time of DRM detection (6.9 ×10−3 [6×10−3–8×10−3] vs. 2.9×10−3 
[2×10−3–4×10−3], P<0.001).
We obtained similar findings using modified Hamming distance calculation. Hamming 
distance changes across the pol sequence (i.e., % median mismatch [95% CI]) from pre-
ART to final LLV sequences were greater in subjects with new DRM compared to subjects 
without DRM in both nucleotides 1.4 % [1.1%, 1.8%] vs. 1.1 % [0.7%, 1.4%]; P=0.02, and 
amino acids 1.6 % [1.1%, 1.9%] vs. 1.0 % [0.5%, 1.2%]; P=0.001. Nucleotides and amino 
acid changes over non-DRM sites were similar in both groups (1.1% [0.9%, 1.7%] vs. 1.0 % 
[0.7%, 1.4%]; P=0.11 and 1.2 % [0.8%, 1.6%] vs. 1.0 % (0.6%, 1.4%]; P=0.25, 
respectively).
Without exclusion of DRM positions, synonymous substitution rates (dS) were similar 
between subjects with new DRM vs. subjects without DRM (median dS [95% CI]: 0.018 
(0.006- 0.040) vs. 0.020 (0.006 – 0.025), p=0.54 but non-synonymous substitution rate (dN) 
was higher in subjects with new DRM: 0.003 (0.003 – 0.005) vs. 0.001 (0 – 0.003), p=0.03. 
With exclusion of DRM positions, synonymous and non-synonymous substitution rates were 
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both similar between DRM vs. non-DRM groups (dS: 0.016 (0.007 – 0.034) vs. 0.017 (0.006 
– 0.023), p=0.48 and dN: 0.000 (0 – 0.002) vs. 0.001 (0–0.003), p=0.75). Additionally, we 
did not detect any difference in synonymous substitution rates over non-DRM sites based on 
initial regimens (p=0.16).
As shown in Table 1, higher rates of nucleotide substitution across the pol region were 
associated with higher HIV-1 RNA levels during LLV (first, minimum, maximum and 
HIV-1 RNA area under the curve, all P<0.05, r=0.31 to 0.55).
Restricting to non-DRM sites, nucleotide substitution rate was also positively correlated 
with HIV-1 RNA levels during LLV (P<0.05 for each metric, r=0.27 to 0.51) except 
maximum VL which did not reach statistical significance [P=0.07, r=0.25]). Similar results 
were seen when modified Hamming distance was used in the association analyses. Age, sex, 
race, pre-ART VL, pre-ART CD4 and duration of LLV were not associated with HIV-1 
sequence evolution during LLV.
Similarly in Table 2, synonymous and non-synonymous substitution rates were associated 
with higher HIV-1 RNA levels across pol sequence and restricting to non-DRM sites. In 
particular, non-synonymous substitution rate across pol sequence was strongly associated 
with first VL during LLV.
Discussion
By using continuous metrics of HIV sequence changes, we separately examined HIV-1 
evolution at DRM and non-DRM sites in patients experiencing LLV during first-line ART. 
Analogous methods have been used to quantify HIV evolution rates within versus outside 
cytotoxic T-lymphocyte-targeted regions [12]. To our knowledge, ours is the first study to 
apply these methods to LLV and also interrogate sequence changes at non-DRM sites. We 
found greater HIV-1 evolution from the pre-ART to the final sequence of LLV in subjects 
who developed DRMs compared to subjects who did not develop DRM driven by the 
evolution at the DRM sites. Among subjects with emergent DRM, those with DRM detected 
at VL > 200 copies/mL had much greater sequence changes compared to those with DRM 
detected at VL < 200 copies/mL. These results were consistent using phylogenetic analysis 
and modified Hamming distances. The magnitude of LLV was the primary driver of 
evolutionary rate at DRM as well as non-DRM sites. This agrees with the strong association 
between higher VL and DRM emergence in these subjects [6]. Additionally, a prior study 
also found a relationship between low-level viremia (time adjusted AUC of VL) and 
sequence evolution in the env region among patients from whom virus was recovered by 
coculture of peripheral blood mononuclear cells after 2 years of plasma suppression [18]. 
The methods employed in this study should be applied to larger populations and a broader 
array of regimens to further characterize HIV-1 evolution kinetics that promote new DRM 
during LLV. Nevertheless, the study provides insights that may be applicable to the 
management of patients with persistent LLV during ART.
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Table 2
Association of HIV-1 sequence synonymous (dS) and non-synonymous (dN) substitution rates with subjects’ 
baseline characteristics and HIV-1 metrics during low-level viremia.
Pol sequence Non-drm sites
dS dN dS dN
Sex (0.64) (0.99) (0.97) (0.84)
Race (0.44) (0.98) (0.39) (0.44)
Age (years) (0.08) (0.44) (0.11) (0.37)
Pretreatment VL (log10 copies/mL) (0.35) (0.05) (0.43) (0.80)
Pretreatment CD4 (cells/mm3) (0.60) (0.83) (0.78) (0.22)
Length of low-level viremia (weeks) (0.92) (0.22) (0.69) (0.54)
First VL during LLV (copies/mL)
0.46 0.52 0.45 0.38
(<0.01) (<0.001) (<0.0001) (<0.001)
Minimum VL during LLV (copies/mL)
0.29 0.39 0.29 0.29
(<0.05) (<0.05) (<0.01) (<0.05)
Maximum VL during LLV (copies/mL)
0.31 0.35 0.32 0.30
(<0.05) (<0.05) (<0.01) (<0.05)
Time adjusted area under the curve (copies/mL)
0.29 0.40 0.30 0.27
(0.05) (<0.05) (<0.01) (<0.05)
Displayed are Spearman correlations (with significance levels in parentheses). For sex and race and other baseline characteristics, only significance 
levels are shown (based on Kruskal-Wallis or Wilcoxon rank-sum tests).
DRM, drug resistance mutation; LLV, low-level viremia
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